Role of Sub-Conjunctival Bevacizumab in Post Pterygium Excision Management

Completed · Phase 4

Conditions studied: Pterygium

In brief

A pterygium is a fibrovascular growth originating from the conjunctiva that grows onto the surface of the cornea. Frequently, these pterygia will recur even after surgical resection. Bevacizumab is an inhibitor of angiogenesis, which is needed for recurrent growth. The use of bevacizumab is poorly understood in inhibiting pterygium growth. The objective of this study is to compare the effects of wound healing and recurrence rates in postoperative bevacizumab versus pterygium excision alone.

Key facts

Study ID

NCT01736449

Run by

Arrowhead Regional Medical Center

People needed

31

Starts

2011-04-01

Expected to finish

2012-04-01

Last updated by the study team

2012-11-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• any patient 18 years of age or older with a primary pterygium that extends at least 2 mm past the limbus

You may not qualify if…

• history of glaucoma
• previous ocular surgery
• steroid-response glaucoma
• previous myocardial infarct
• bleeding disorder
• pregnancy
• lack of patient cooperation

Where it is running

• Arrowhead Regional Medical Center — Colton, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.